Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A greater visit frequency between the diabetes mellitus 1 (DM1) patient and the medical team increases the possibilities to improve metabolic control. The support of telematic visits can support the patient and the health system.
Patients and Method: 160 patients (from 5 participating centres) with type 1 diabetes mellitus (DM1) candidates for improved metabolic control selected according to inclusion and exclusion criteria. The telecare system used is comprised of the patient Unit and the doctor Unit. The system allows the patient to send glucose values, insulin doses, carbohydrate contribution and other events via the internet. Both the patient and the professional can use this information via the telecare system platform.
Work hypothesis
The application of interactive telematic systems between patient-health team will improve the cost effectiveness of care programmes for optimisation of metabolic control directed towards diabetes mellitus (DM1) patients.
Objectives:
General Objective Evaluate the impact of the telecare system on the efficiency of economic and clinical management of human and material resources directed to a program of metabolic control optimisation in diabetes mellitus 1 (DM1) patients as well as the level of metabolic control and the quality of life of the patients.
Specific objectives
*Title: Multicentric random, prospective, open and comparative intervention study evaluating the efficiency of the implementation in the Spanish Health System of a telematic system applied to metabolic control optimization for type 1 diabetes mellitus (DM1) patients.
Protocol:
1) Pre-intervention. After the patient is informed and accepts the protocol they make 2 visits for planning individual treatment. 2) Random Assignment in 2 Groups: A) Intervention (telecare system). B) Control. The intervention group patients will be trained in the telecare system machine. Both groups will make the same number of 6 visits over 6 months: Intervention Group (5 telematics and 1 hospital), Control group (6 hospital). Results will be assessed at 3 and 6 months and reassessed at 12 months.
Patients The objective of the present study is to demonstrate that telematic control of diabetes mellitus is not inferior to the face to face visit control system, while showing an added value an important reduction in costs. Cost information from three studies have been used for the calculation of the sample 2,3,20 in diabetes mellitus 1 (DM1) patients, some followed in a telematic form (210 ± 184€) and other in the form of face to face visits (376 ± 278€). Relating to this, 72 patients per group are needed to obtain a statistical power of 99% and an alpha level of 0.05 (two-sided). 80 patients per group will be needed to be randomised taking into account a 10% loss percentage.
Participating Centres
Each arm will include 80 patients, 160 as a total.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Interventional telematic | Experimental | 80 patients will be included in this arm. They will receive 5 telematic visits (Telecare system) and 2 face to face visits. |
|
| Control | Other | 80 patients will be included in this arm. They will receive 7 face-to-face visits (not telematic). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Control | Other | 7 face-to-face visits. |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Optimise metabolic control |
| Month 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Patient costs | Time, expenses and ordinary activity (studies and work) that the patient could not do in order to attend to the face-to-face visits. | Month 6 |
| Medical team costs | Time, expenses and healthcare issues used in the follow-up phase of the metabolic control. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Enric Esmatjes, MD and PhD | Hospital Clínic de Barcelona (CIBERDEM) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Clínic de Barcelona | Barcelona | Barcelona | 08036 | Spain | ||
| Hospital Clínico de Madrid |
Not provided
| Label | URL |
|---|---|
| CIBERDEM website, including a description of TELEMED-DIABETES | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Telecare system | Device | 5 telematic visits and 2 face-to-face visits. |
|
|
| Month6 |
| Quality of life | Quality-of-life questionnaire designed for diabetes mellitus (EsDQOL) and standardised instrument for use as a measure of health outcome (EuroQoL). | Month 12 |
| Treatment adherence | Self-Care Inventory-revised (SCI-R), a self-report measure of perceived adherence to diabetes self-care recommendations, among adults with diabetes. | Month 12 |
| Madrid |
| Madrid |
| 28040 |
| Spain |
| Hospital de Cruces | Barakaldo | Spain | 48903 | Spain |
| Hospital Carlos Haya | Málaga | Spain | 29010 | Spain |
| Hospital Clínico de Valencia | Valencia | Spain | 46010 | Spain |
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| D008659 | Metabolic Diseases |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided